User profiles for "author:Thomas Ciulla"
T Ciulla, TA Ciulla, Thomas CiullaChief Medical Officer, Viridian; Volunteer Clinical Professor, Indiana Univ Schl of Medicine Verified email at midwesteye.com Cited by 29118 |
Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies
TA Ciulla, AG Amador, B Zinman - Diabetes care, 2003 - Am Diabetes Assoc
Diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of
blindness in the working-age population of most developed countries. The increasing …
blindness in the working-age population of most developed countries. The increasing …
Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update
TA Ciulla, MB Starr, S Masket - Ophthalmology, 2002 - Elsevier
PURPOSE: To assess commonly used cataract surgery bacterial endophthalmitis
prophylaxis techniques based on a systematic literature review and evidence rating …
prophylaxis techniques based on a systematic literature review and evidence rating …
Regulation of retinal and optic nerve blood flow
Blood flow to the retina and optic nerve remains constant over a range of elevated
intraocular pressure or mean arterial pressure, independent of sympathetic activation …
intraocular pressure or mean arterial pressure, independent of sympathetic activation …
Vascular endothelial growth factor–induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform–selective …
Increased vascular permeability and excessive neovas-cularization are the hallmarks of
endothelial dysfunction, which can lead to diabetic macular edema and proliferative diabetic …
endothelial dysfunction, which can lead to diabetic macular edema and proliferative diabetic …
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study
OBJECTIVES:: To determine the long-term effects of ranibizumab (RBZ) in patients with
diabetic macular edema (DME). DESIGN:: Prospective, randomized, interventional …
diabetic macular edema (DME). DESIGN:: Prospective, randomized, interventional …
Intravitreal triamcinolone acetonide in exudative age-related macular degeneration
Purpose: To examine the effects of intravitreal injection of 4.0 mg triamcinolone acetonide on
the visual and clinical course of exudative age-related macular degeneration. Methods: A …
the visual and clinical course of exudative age-related macular degeneration. Methods: A …
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study
JS Heier, AN Antoszyk, PR Pavan, SR Leff… - Ophthalmology, 2006 - Elsevier
OBJECTIVE: To assess safety of repeated intravitreal injections of ranibizumab in treating
neovascular age-related macular degeneration (AMD), and to assess changes in visual …
neovascular age-related macular degeneration (AMD), and to assess changes in visual …
Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema
Objective To assess the efficacy and safety of intravitreal inserts releasing 0.2 μg/day (low
dose) or 0.5 μg/day (high dose) fluocinolone acetonide (FA) in patients with diabetic macular …
dose) or 0.5 μg/day (high dose) fluocinolone acetonide (FA) in patients with diabetic macular …
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study
Objective To investigate the safety and efficacy of intravitreal ranibizumab treatment
combined with verteporfin photodynamic therapy (PDT) in patients with predominantly …
combined with verteporfin photodynamic therapy (PDT) in patients with predominantly …
Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema
DG Callanan, S Gupta, DS Boyer, TA Ciulla, MA Singer… - Ophthalmology, 2013 - Elsevier
Purpose To evaluate Ozurdex (dexamethasone intravitreal implant [DEX implant]; Allergan,
Inc, Irvine, CA) 0.7 mg combined with laser photocoagulation compared with laser alone for …
Inc, Irvine, CA) 0.7 mg combined with laser photocoagulation compared with laser alone for …